The T Helper Cell Shift in AIDS

Significance for Pharmacotherapy

Mario Clerici, Gene M. Shearer

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We recently postulated that susceptibility to HIV infection and progression of HIV-infected individuals to AIDS is controlled by cytokines that regulate 2 functionally distinct subsets of T helper (TH) lymphocytes. These subsets are TH1, which mainly enhance cell-mediated immunity and are regulated by type 1 cytokines. and TH2, which mainly augment antibody production and are regulated by type 2 cytokines. HIV-seronegative individuals exposed to HIV may exhibit strong HIV-specific T cell-mediated immunity, since both HIV-specific T helper and T cytotoxic lymphocytes are activated in the absence of seroconversion and disease. Additionally, during progression of HIV-seropositive individuals to AIDS. a decline is observed in type 1 cytokines as well as an increase in the production of type 2 cytokines by HIV-positive peripheral blood mononuclear cells stimulated in vitro. The type 1 to type 2 switch is predictive for the following clinically relevant events: (a) reduction in CD4+ cell counts; (b) time to diagnosis of AIDS; and (c) time to death. The manipulation of the immune response to induce and strengthen HIV-specific immunity may thus be useful in the management of HIV infection.

Original languageEnglish
Pages (from-to)95-101
Number of pages7
JournalClinical Immunotherapeutics
Volume3
Issue number2
DOIs
Publication statusPublished - 1995

Fingerprint

Helper-Inducer T-Lymphocytes
Acquired Immunodeficiency Syndrome
HIV
Drug Therapy
Cytokines
Cellular Immunity
HIV Infections
HIV-2
CD4 Lymphocyte Count
Antibody Formation
Immunity
Blood Cells
T-Lymphocytes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pharmacology (medical)

Cite this

The T Helper Cell Shift in AIDS : Significance for Pharmacotherapy. / Clerici, Mario; Shearer, Gene M.

In: Clinical Immunotherapeutics, Vol. 3, No. 2, 1995, p. 95-101.

Research output: Contribution to journalArticle

@article{956acfafbc6e4b9e8856c0a9bc66872c,
title = "The T Helper Cell Shift in AIDS: Significance for Pharmacotherapy",
abstract = "We recently postulated that susceptibility to HIV infection and progression of HIV-infected individuals to AIDS is controlled by cytokines that regulate 2 functionally distinct subsets of T helper (TH) lymphocytes. These subsets are TH1, which mainly enhance cell-mediated immunity and are regulated by type 1 cytokines. and TH2, which mainly augment antibody production and are regulated by type 2 cytokines. HIV-seronegative individuals exposed to HIV may exhibit strong HIV-specific T cell-mediated immunity, since both HIV-specific T helper and T cytotoxic lymphocytes are activated in the absence of seroconversion and disease. Additionally, during progression of HIV-seropositive individuals to AIDS. a decline is observed in type 1 cytokines as well as an increase in the production of type 2 cytokines by HIV-positive peripheral blood mononuclear cells stimulated in vitro. The type 1 to type 2 switch is predictive for the following clinically relevant events: (a) reduction in CD4+ cell counts; (b) time to diagnosis of AIDS; and (c) time to death. The manipulation of the immune response to induce and strengthen HIV-specific immunity may thus be useful in the management of HIV infection.",
author = "Mario Clerici and Shearer, {Gene M.}",
year = "1995",
doi = "10.1007/BF03259271",
language = "English",
volume = "3",
pages = "95--101",
journal = "BioDrugs",
issn = "1172-7039",
publisher = "Adis International Ltd",
number = "2",

}

TY - JOUR

T1 - The T Helper Cell Shift in AIDS

T2 - Significance for Pharmacotherapy

AU - Clerici, Mario

AU - Shearer, Gene M.

PY - 1995

Y1 - 1995

N2 - We recently postulated that susceptibility to HIV infection and progression of HIV-infected individuals to AIDS is controlled by cytokines that regulate 2 functionally distinct subsets of T helper (TH) lymphocytes. These subsets are TH1, which mainly enhance cell-mediated immunity and are regulated by type 1 cytokines. and TH2, which mainly augment antibody production and are regulated by type 2 cytokines. HIV-seronegative individuals exposed to HIV may exhibit strong HIV-specific T cell-mediated immunity, since both HIV-specific T helper and T cytotoxic lymphocytes are activated in the absence of seroconversion and disease. Additionally, during progression of HIV-seropositive individuals to AIDS. a decline is observed in type 1 cytokines as well as an increase in the production of type 2 cytokines by HIV-positive peripheral blood mononuclear cells stimulated in vitro. The type 1 to type 2 switch is predictive for the following clinically relevant events: (a) reduction in CD4+ cell counts; (b) time to diagnosis of AIDS; and (c) time to death. The manipulation of the immune response to induce and strengthen HIV-specific immunity may thus be useful in the management of HIV infection.

AB - We recently postulated that susceptibility to HIV infection and progression of HIV-infected individuals to AIDS is controlled by cytokines that regulate 2 functionally distinct subsets of T helper (TH) lymphocytes. These subsets are TH1, which mainly enhance cell-mediated immunity and are regulated by type 1 cytokines. and TH2, which mainly augment antibody production and are regulated by type 2 cytokines. HIV-seronegative individuals exposed to HIV may exhibit strong HIV-specific T cell-mediated immunity, since both HIV-specific T helper and T cytotoxic lymphocytes are activated in the absence of seroconversion and disease. Additionally, during progression of HIV-seropositive individuals to AIDS. a decline is observed in type 1 cytokines as well as an increase in the production of type 2 cytokines by HIV-positive peripheral blood mononuclear cells stimulated in vitro. The type 1 to type 2 switch is predictive for the following clinically relevant events: (a) reduction in CD4+ cell counts; (b) time to diagnosis of AIDS; and (c) time to death. The manipulation of the immune response to induce and strengthen HIV-specific immunity may thus be useful in the management of HIV infection.

UR - http://www.scopus.com/inward/record.url?scp=0028878496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028878496&partnerID=8YFLogxK

U2 - 10.1007/BF03259271

DO - 10.1007/BF03259271

M3 - Article

VL - 3

SP - 95

EP - 101

JO - BioDrugs

JF - BioDrugs

SN - 1172-7039

IS - 2

ER -